Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.
Jillian H
JH
Hurst
D000486:Allergy and Immunology / Q000266:history*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001363:Awards and Prizes; D060908:CTLA-4 Antigen / Q000276:immunology; D017326:Clinical Trials, Phase III as Topic; D004354:Drug Screening Assays, Antitumor; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007157:Immunologic Surveillance; D007167:Immunotherapy / Q000266:history*; D000074324:Ipilimumab; D008213:Lymphocyte Activation; D008495:Medical Oncology / Q000266:history*; D008545:Melanoma / Q000556:secondary / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009518:New York; D016032:Randomized Controlled Trials as Topic; D011948:Receptors, Antigen, T-Cell / Q000737:chemistry / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013781:Texas
D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab; D011948:Receptors, Antigen, T-Cell